Roche, Biogen Idec Suspend Tests for Arthritis Drug (Update3) - Bloomberg
Links shared publicly online about this topic.
- 1,329total visits
Roche, Biogen Idec Suspend Tests for Arthritis Drug (Update3) - Bloomberg
Roche Holding AG and Biogen Idec Inc. are suspending development of the ocrelizumab treatment for use in arthritis after an independent monitoring board said safety risks outweigh benefits observed in these patients.
View full resource at bloomberg.com
Tags: Infection, Arthritis, Arthritis Medication, Drug, Biogen Idec, Safety
Most Recently Shared on March 8, 2010 at 3:45 pm By:
Serious infections halt arthritis drug trial. http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aSvybWA4wXuA
Advertisement
